Stock Analysis on Net
Stock Analysis on Net

Celgene Corp. (NASDAQ:CELG)

$22.49

This company has been moved to the archive! The financial data has not been updated since October 31, 2019.

Economic Value Added (EVA)

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check

Economic Profit

Celgene Corp., economic profit calculation

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
Net operating profit after taxes (NOPAT)1
Cost of capital2
Invested capital3
 
Economic profit4

Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).

1 NOPAT. See details »

2 Cost of capital. See details »

3 Invested capital. See details »

4 2018 Calculation
Economic profit = NOPAT – Cost of capital × Invested capital
= × =


An analysis of the financial performance from 2014 to 2018 reveals a consistent failure to generate positive economic profit, although a significant recovery trend emerged in the final year of the period.

Net Operating Profit After Taxes (NOPAT)
NOPAT remained relatively stagnant between 2014 and 2017, fluctuating within a narrow range of 1,787 million to 1,954 million US$. However, a substantial increase occurred in 2018, where NOPAT rose to 4,676 million US$, representing a growth of approximately 144% over the previous year.
Invested Capital
A strong upward trend in invested capital is observed throughout the period. Capital grew from 9,844 million US$ in 2014 to 27,773 million US$ by 2018. The most aggressive expansion occurred between 2014 and 2015, where invested capital nearly doubled, increasing by approximately 84%.
Cost of Capital
The cost of capital exhibited a steady downward trajectory, decreasing from a peak of 21.20% in 2014 to 17.93% in 2018. This gradual decline suggests a reduction in the weighted average cost of financing over the five-year duration.
Economic Profit Analysis
Economic profit remained negative for the entire duration, indicating that the returns generated were insufficient to cover the cost of the capital employed. The deficit widened sharply in 2015, dropping from -261 million US$ to -1,735 million US$, primarily driven by the massive increase in invested capital that did not yield an immediate corresponding increase in NOPAT. While the economic profit remained depressed between 2015 and 2017, it improved significantly in 2018 to -305 million US$, driven by the surge in NOPAT and the lowest recorded cost of capital.

The data indicates that while aggressive capital investment initially eroded economic value, the sharp increase in operating profitability in 2018 has moved the organization significantly closer to achieving a positive economic profit.



Net Operating Profit after Taxes (NOPAT)

Celgene Corp., NOPAT calculation

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
Net income
Deferred income tax expense (benefit)1
Increase (decrease) in allowance for doubtful accounts2
Increase (decrease) in deferred revenue3
Increase (decrease) in equity equivalents4
Interest expense
Interest expense, operating lease liability5
Adjusted interest expense
Tax benefit of interest expense6
Adjusted interest expense, after taxes7
(Gain) loss on marketable securities
Investment income, before taxes
Tax expense (benefit) of investment income8
Investment income, after taxes9
Net operating profit after taxes (NOPAT)

Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).

1 Elimination of deferred tax expense. See details »

2 Addition of increase (decrease) in allowance for doubtful accounts.

3 Addition of increase (decrease) in deferred revenue.

4 Addition of increase (decrease) in equity equivalents to net income.

5 2018 Calculation
Interest expense on capitalized operating leases = Operating lease liability × Discount rate
= × =

6 2018 Calculation
Tax benefit of interest expense = Adjusted interest expense × Statutory income tax rate
= × 21.00% =

7 Addition of after taxes interest expense to net income.

8 2018 Calculation
Tax expense (benefit) of investment income = Investment income, before tax × Statutory income tax rate
= × 21.00% =

9 Elimination of after taxes investment income.


Net Income
The net income demonstrates a fluctuating yet generally upward trend over the five-year period. Starting at $2,000 million in 2014, it experienced a notable decline to $1,602 million in 2015. This was followed by a recovery in 2016, reaching $1,999 million, subsequently increasing more substantially in 2017 to $2,940 million. The most significant growth occurred in 2018, with net income reaching $4,046 million, more than doubling the 2015 low point and exceeding the 2014 figure by a substantial margin. This trend suggests an overall improvement in profitability, with a particularly strong performance in the final year under review.
Net Operating Profit After Taxes (NOPAT)
NOPAT shows a more consistent pattern over the period, with marginal fluctuations between 2014 and 2017. It started at $1,826 million in 2014, experienced a slight decrease to $1,787 million in 2015, then increased moderately to $1,954 million in 2016, before a small decrease to $1,913 million in 2017. A significant increase occurred in 2018, with NOPAT more than doubling to $4,676 million. This sharp rise contrasts with the relative stability of previous years and indicates a substantial improvement in operational efficiency or profitability in 2018. The disparity between net income and NOPAT values also suggests changes in tax impact or non-operating items affecting earnings.
Overall Analysis
Both net income and NOPAT reveal a period of relative stability or moderate variation from 2014 to 2017, followed by significant growth in 2018. The sharp increase in 2018 for both metrics represents a notable positive shift in financial performance. While net income shows some volatility, NOPAT is comparatively stable until the final year, indicating consistent operating profitability prior to the substantial improvement. The data suggests the company may have implemented effective strategies or benefited from market conditions that dramatically enhanced profitability and operational results in 2018.


Cash Operating Taxes

Celgene Corp., cash operating taxes calculation

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
Provision for taxes on income
Less: Deferred income tax expense (benefit)
Add: Tax savings from interest expense
Less: Tax imposed on investment income
Cash operating taxes

Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).


Provision for taxes on income
The provision for taxes on income exhibited fluctuations over the observed period. Starting at $328 million in 2014, it increased to $422 million in 2015, then decreased to $373 million in 2016. A significant rise occurred in 2017, reaching $1,374 million, followed by a notable decline to $786 million in 2018. This pattern indicates volatility in the tax obligations estimated for income taxes, with a pronounced peak in 2017.
Cash operating taxes
Cash operating taxes showed a similar volatile pattern. Beginning at $654 million in 2014, the value fell to $555 million in 2015, then rose substantially to $884 million in 2016. A dramatic increase was observed in 2017, peaking at $2,853 million. The following year, 2018, saw a sharp decrease to $903 million. This trend suggests a significant variation in the actual cash tax payments, with the highest cash outflow recorded in 2017.
Comparative insights
Both provisions for income taxes and cash operating taxes demonstrate notable volatility with peaks in 2017. The magnitude of cash operating taxes consistently exceeds the provision for taxes, particularly evident in 2017 when cash taxes were more than double the provision amount. This discrepancy might indicate timing differences or adjustments between accrued tax expenses and actual cash payments during these periods.
Overall trend
The data reveals inconsistent patterns in both tax provisions and cash taxes over the five years, with a significant spike in 2017 followed by a decrease in 2018. The spikes may be linked to underlying changes in earnings, tax planning strategies, or external tax regulations affecting the company’s tax liabilities and payments.


Invested Capital

Celgene Corp., invested capital calculation (financing approach)

US$ in millions

Microsoft Excel
Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
Short-term borrowings and current portion of long-term debt
Long-term debt, net of discount, excluding current portion
Operating lease liability1
Total reported debt & leases
Stockholders’ equity
Net deferred tax (assets) liabilities2
Allowance for doubtful accounts3
Deferred revenue4
Equity equivalents5
Accumulated other comprehensive (income) loss, net of tax6
Adjusted stockholders’ equity
Construction in progress7
Debt securities available-for-sale and equity investments with readily determinable fair values8
Invested capital

Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).

1 Addition of capitalized operating leases.

2 Elimination of deferred taxes from assets and liabilities. See details »

3 Addition of allowance for doubtful accounts receivable.

4 Addition of deferred revenue.

5 Addition of equity equivalents to stockholders’ equity.

6 Removal of accumulated other comprehensive income.

7 Subtraction of construction in progress.

8 Subtraction of debt securities available-for-sale and equity investments with readily determinable fair values.


Total reported debt & leases
The total reported debt and leases exhibited a significant upward trend over the five-year period. Starting at $7,068 million in 2014, the figure more than doubled by 2015 to $14,456 million. It then remained relatively stable in 2016 around $14,480 million before increasing consistently to reach $20,645 million by 2018. This indicates a growing reliance on debt and lease obligations to finance operations or investments during this timeframe.
Stockholders’ equity
Stockholders’ equity showed some fluctuations with no clear positive trend. The equity started at $6,525 million in 2014, decreased to $5,919 million in 2015, then increased gradually in 2016 and 2017 to reach $6,921 million. However, in 2018, equity declined again to $6,161 million. This pattern may suggest variability in retained earnings, issuance or repurchase of shares, or other equity-related activities affecting the net book value of shareholders' investment.
Invested capital
Invested capital expanded substantially over the period assessed. It nearly doubled from $9,844 million in 2014 to $18,136 million in 2015 and then continued to grow steadily to $18,672 million in 2016 and $18,857 million in 2017. A marked increase occurred in 2018, with invested capital soaring to $27,773 million. This substantial growth points to increased capital deployment into long-term assets or working capital, possibly reflecting strategic expansion or acquisition initiatives supported partially by rising debt levels.


Cost of Capital

Celgene Corp., cost of capital calculations

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2018-12-31).

1 US$ in millions

2 Equity. See details »

3 Debt. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt3 ÷ = × × (1 – 35.00%) =
Operating lease liability4 ÷ = × × (1 – 35.00%) =
Total:

Based on: 10-K (reporting date: 2017-12-31).

1 US$ in millions

2 Equity. See details »

3 Debt. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt3 ÷ = × × (1 – 35.00%) =
Operating lease liability4 ÷ = × × (1 – 35.00%) =
Total:

Based on: 10-K (reporting date: 2016-12-31).

1 US$ in millions

2 Equity. See details »

3 Debt. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt3 ÷ = × × (1 – 35.00%) =
Operating lease liability4 ÷ = × × (1 – 35.00%) =
Total:

Based on: 10-K (reporting date: 2015-12-31).

1 US$ in millions

2 Equity. See details »

3 Debt. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt3 ÷ = × × (1 – 35.00%) =
Operating lease liability4 ÷ = × × (1 – 35.00%) =
Total:

Based on: 10-K (reporting date: 2014-12-31).

1 US$ in millions

2 Equity. See details »

3 Debt. See details »

4 Operating lease liability. See details »



Economic Spread Ratio

Celgene Corp., economic spread ratio calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
Selected Financial Data (US$ in millions)
Economic profit1
Invested capital2
Performance Ratio
Economic spread ratio3
Benchmarks
Economic Spread Ratio, Competitors4
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).

1 Economic profit. See details »

2 Invested capital. See details »

3 2018 Calculation
Economic spread ratio = 100 × Economic profit ÷ Invested capital
= 100 × ÷ =

4 Click competitor name to see calculations.


The financial performance from 2014 to 2018 is characterized by persistent negative economic profit, indicating that the returns generated on invested capital were insufficient to cover the cost of that capital throughout the period. However, a significant recovery trend is observed in the final year of the sequence.

Economic Profit Trends
Economic profit experienced a sharp decline between 2014 and 2015, moving from -261 million USD to -1,735 million USD. This level of loss remained relatively stagnant through 2016 and 2017. A substantial recovery occurred in 2018, where economic profit improved to -305 million USD, representing a near-return to 2014 levels despite a much larger capital base.
Invested Capital Growth
Invested capital exhibited aggressive growth over the five-year period. A primary surge occurred between 2014 and 2015, with capital increasing from 9,844 million USD to 18,136 million USD. Following a period of relative stability from 2015 to 2017, another significant expansion was recorded in 2018, reaching 27,773 million USD.
Economic Spread Ratio Analysis
The economic spread ratio mirrored the volatility of economic profit, dropping sharply from -2.65% in 2014 to a low of -9.57% in 2015. The ratio remained deeply negative through 2017, reflecting a period of significant value destruction. A notable reversal is observed in 2018, as the ratio improved to -1.10%, signaling that the company narrowed the gap between its return on capital and its cost of capital.

The overall trend suggests a period of heavy capital investment coinciding with a period of economic loss between 2015 and 2017, followed by a strong efficiency gain in 2018. The improvement in the economic spread ratio in 2018 is particularly significant given it occurred alongside the highest level of invested capital recorded in the period.



Economic Profit Margin

Celgene Corp., economic profit margin calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
Selected Financial Data (US$ in millions)
Economic profit1
 
Net product sales
Add: Increase (decrease) in deferred revenue
Adjusted net product sales
Performance Ratio
Economic profit margin2
Benchmarks
Economic Profit Margin, Competitors3
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).

1 Economic profit. See details »

2 2018 Calculation
Economic profit margin = 100 × Economic profit ÷ Adjusted net product sales
= 100 × ÷ =

3 Click competitor name to see calculations.


An analysis of the economic performance from 2014 to 2018 reveals a period of substantial economic value destruction followed by a significant recovery phase, occurring alongside a consistent increase in top-line revenue.

Adjusted Net Product Sales
A continuous upward trajectory in adjusted net product sales is observed, increasing from 7,569 million US$ in 2014 to 15,302 million US$ by 2018. This represents a sustained expansion in revenue generation throughout the five-year period.
Economic Profit Trends
Economic profit remained negative throughout the analyzed period, indicating that the company did not generate returns in excess of its cost of capital. A sharp decline occurred between 2014 and 2015, with losses widening from 261 million US$ to 1,735 million US$. Following a period of relative stagnation between 2015 and 2017, a substantial recovery was recorded in 2018, with the deficit narrowing to 305 million US$.
Economic Profit Margin Analysis
The economic profit margin tracked the volatility of the absolute economic profit figures. The margin deteriorated sharply to its lowest point of -18.87% in 2015. From 2016 onward, a consistent trend of improvement is evident, with the margin narrowing to -15.50% in 2016, -12.51% in 2017, and finally reaching -1.99% in 2018. This progression indicates that while economic value added remained negative, the gap between operating returns and the cost of capital narrowed significantly relative to sales growth by the end of the period.